Pharmacy & Therapeutics- July 2008 - (Page 416) CONTINUING EDUCATION CREDIT 5-HT1b/1d agonist: Differential effects of propranolol, nadolol, and metoprolol. J Clin Pharmacol 2001;52:69–76. 211. Cutrer FM, Goadsby PJ, Ferrari MD, et al. Priorities for triptan treatment attributes and the implications for selecting an oral triptan for acute migraine: A study of U.S. primary care physicians. Clin Ther 2004;26(9):1533–1545. 212. Dahlof CG. Non-oral formulations of triptans and their use in acute migraine. Curr Pain Headache 2005;9(3):206–212. 213. Diamond S, Freitag FG, Feoktistov A, et al. Sumatriptan 6 mg subcutaneous as an effective migraine treatment in patients with cutaneous allodynia who historically fail to respond to oral triptans. Headache Pain 2007;8(1):13–18. 214. Winner P, Adelman J, Aurora S, et al. Efficacy and tolerability of sumatriptan injection for the treatment of morning migraine: Two multicenter, prospective, randomized, double-blind, controlled studies in adults. Clin Ther 2006;28(10):1582–1591. 215. Winner P, Rothner AD, Wooten JD, et al. Sumatriptan nasal spray in adolescent migraineurs: A randomized, double-blind, placebocontrolled, acute study. Headache 2006;46(2):212–222. 216. Goadsby PJ, Yates R. Zolmitriptan intranasal: A review of the pharmacokinetics and clinical efficacy. Headache 2006;46(1):138–149. 217. Dowson AJ, MacGregor EA, Purdy RA, et al. Zolmitriptan orally disintegrating tablet is effective in the acute treatment of migraine. Cephalalgia 2002;22(2):101–106. 218. Dodick DW, Silberstein S, Daholf CG. Is there a preferred triptan? (Editorial) Headache 2002;42:1–7. 219. Adelman JU, Lipton RB, Ferrari MD, et al. Comparison of rizatriptan and other triptans on stringent measures of efficacy. Neurology 2001;57:1377–1383. 220. Dowson AJ, Mathew NT, Pascual J. Review of clinical trials using acute intervention with oral triptans for migraine management. Int J Clin Pract 2007;60(6):698–706. 221. Sullivan JT, Preston KL, Testa MP, et al. Psychoactivity and abuse potential of sumatriptan. Clin Pharmacol Ther 1992;52(6):635–642. 222. Katsarava Z, Fritsche G, Muessig M, et al. Clinical features of withdrawal headache following overuse of triptans and other headache drugs. Neurology 2001;57:1694–1698. 223. Jones J, Sklar D, Dougherty J, et al. Randomized double-blind trial of intravenous prochlorperazine for the treatment of acute headache. JAMA 1989;261(8):1174–1176. 224. Kabbouche MA, Vockell AL, LeCates SL, et al. Tolerability and effectiveness of prochlorperazine for intractable migraine in children. Pediatrics 2001;107(4):E62 and online. 225. Coppola M, Yealy DM, Leibold RA. Randomized, placebo-controlled evaluation of prochlorperazine versus metoclopramide for emergency department treatment of migraine headache. Ann Emerg Med 1995;26:541–567. 226. Jones J, Pack S, Chun E. Intramuscular prochlorperazine versus metoclopramide as single-agent therapy for the treatment of migraine headache. Ann Emerg Med 1995;26:541–546. 227. Seim MB, March JA, Dunn KA. Intravenous ketorolac vs. intravenous prochlorperazine for the treatment of migraine headaches. Acad Emerg Med 1998;5(6):573–576. 228. Jones EB, Gonzalez ER, Boggs JG, et al. Safety and efficacy of rectal prochlorperazine for the treatment of migraine in the emergency department. Ann Emerg Med 1994;24:237–241. 229. Bigal ME, Bordini CA, Speciali JG. Intravenous chlorpromazine in the emergency department treatment of migraines: A randomized controlled trial. J Emerg Med 2002;23(2):141–148. 230. Cameron JD, Lane PL, Speechley M. Intravenous chlorpromazine vs. intravenous metoclopramide in acute migraine headache. Acad Emerg Med 1995;2(7):597–602. 231. Shrestha M, Singh R, Moreden JE, et al. Ketorolac vs. chlorpromazine in the treatment of acute migraine without aura: A prospective, randomized, double-blind trial. Arch Intern Med 1996;156(15): 1725–1728. 232. Morgenstern LB, Huber JC, Luna-Gonzales H, et al. Headache in the emergency department. Headache 2001;41:537–541. 233. Wang SJ, Silberstein SD, Young WB, et al. Droperidol treatment of status migrainous and refractory migraine. Headache 1997;37(6): 377–382. 234. Richman PB, Allegra J, Eskin B, et al. A randomized clinical trial to assess the efficacy of intramuscular droperidol for the treatment of acute migraine headaches. Am J Emerg Med 2002;20:39–42. 235. Richman P, Reischel U, Ostrow A, et al. Droperidol: A novel therapy for the treatment of acute migraine headache. Am J Emerg Med 1999;17:398–400. 236. Fisher H. A new approach to emergency department therapy of migraine headaches with intravenous haloperidol: A case series. J Emerg Med 1995;13(1):119–122. 237. Colman I, Brown MD, Innes GD, et al. Parenteral metoclopramide for acute migraine: Meta-analysis of randomised controlled trials. BMJ 2004;329(7479):1369–1373. 238. Klapper JA, Stanton JS. Ketorolac versus DHE and metoclopramide in the treatment of migraine headaches. Headache 1991;31(8): 523–524. 239. Schulman EA, Dermott KF. Sumatriptan plus metoclopramide in triptan-nonresponsive migraineurs. Headache 2003;43(7):729–733. 240. Waberzinek G, Markova J, Mastik J. Safety and efficacy of intravenous sodium valproate in the treatment of acute migraine. Neuro Endocrinol Lett 2007;28(1):59–64. 241. Reiter PD, Nickisch J, Merritt G. Efficacy and tolerability of intravenous valproic acid in acute adolescent migraine. Headache 2005; 45(7):899–903. 242. Norton J. Use of valproate in status migraine. Headache 2000;40: 755–757. 243. Edwards KR, Norton J, Behnke M. Comparison of intravenous valproate versus intramuscular dihydroergotamine and metoclopramide for acute treatment of migraine headache. Headache 2001;41:976–980. 244. Mathew NT, Kailasam J. Repetitive intravenous administration of valproate sodium in intractable migraine: Comparison with intravenous dihydroergotamine (DHE) (Abstract). Cephalalgia 2000;20:351. 245. Goldner JA, Levitt LP. Treatment of complicated migraine with sublingual nifedipine. Headache 1987;27:484–486. 246. Yu W, Horowitz SH. Familial hemiplegic migraine and its abortive therapy with intravenous verapamil. Neurology 2001;57:1732. 247. Engindeniz Z, Demircan C, Karli N, et al. Intramuscular tramadol vs diclofenac sodium for the treatment of acute migraine attacks in emergency department: A prospective randomised, double-blind study. J Headache Pain 2005;6:143–148. 248. Cady RK, Schreiber CP, Beach ME, et al. Gelstat migraine (sublingually administered feverfew and ginger compound) for acute treatment of migraine when administered during the mild phase. Med Sci Monit 2005;11(9):165–169. 249. Klapper J, Stanton J. The emergency treatment of acute migraine headache: A comparison of intravenous dihydroergotamine, dexamethasone, and placebo. Cephalalgia 1991;11(Suppl 11):159–160. 250. Corbo J, Esses D, Bijur PE, et al. Randomized clinical trial of intravenous magnesium sulfate as an adjunctive medication for emergency department treatment of migraine headache. Ann Emerg Med 2001;38:621–627. 251. Ramadan NM, Silberstein SD, Freitag FG, et al. Evidence-based guidelines for migraine headache in the primary care setting: Pharmacological management for prevention of migraine. U.S. Headache Consortium. Available at: www/aan.com/professional/ practice. Accessed August 2007. 252. McCory DC, Matchar DB, Rosenberg JH, et al. Evidence-based guidelines for migraine headache: Overview of program description and methodology. Available at: www.aan.com/public/practice guidelines/01.pdf. Accessed August 2007. I Conflict of Interest (COI) Statement Dr. DeMaagd has no relationships to disclose. This article contains discussions of off-label use. The content of this article has been reviewed under Jefferson’s Continuing Medical Education COI policy. 416 P&T® • July 2008 • Vol. 33 No. 7 http://www.aan.com/professionals/practice/pdfs/gl0087.pdf http://www.aan.com/professionals/practice/pdfs/gl0087.pdf
For optimal viewing of this digital publication, please enable JavaScript and then refresh the page. If you would like to try to load the digital publication without using Flash Player detection, please click here.